Product Stability

Fundatmentals of Drug and Product Stability

• Drugs are rarely administered as pure chemical substances because they typically lack the necessary characteristics to produce a designated therapeutic outcome on their own.

• Instead, drugs are usually formulated with other excipients to create a pharmaceutical preparation.

• Drug stability is a critical component of drug dosage design, as it ensures both the chemical and physical integrity of the drug formulation throughout its intended shelf life.

• Ideally, pharmaceutical products should maintain a shelf life of at least $3$ years.

• A product is considered acceptable if it maintains no less than $95\%$ potency during this period.

Classification of Drug Stability

Drug stability is categorized based on the inherent nature of the substance and the requirements for handling:

• Stable if handled correctly: For example, Aspirin, which remains stable under proper storage conditions.

• Very unstable: For example, antibiotic solutions, which degrade rapidly.

• Stable at all conditions: For example, Kaolin, which maintains stability across a wide range of environments.

• Moderately unstable with special handling: For example, vitamins, which require specific conditions (such as protection from light or heat) to remain viable.

Mechanisms of Drug Degradation

Drug degradation typically results from exposure to four environmental factors: heat, oxygen, light, and moisture. These factors trigger four primary degradation processes:

• Oxidation: The loss of electrons or gain of oxygen.

• Photolysis: Chemical breakdown induced by light energy.

• Hydrolysis: Chemical breakdown of molecules through reaction with water.

• Trace Metal Catalysis: Degradation accelerated by small amounts of metal ions.

Critical Considerations for Product Stability

A pharmaceutical "product" refers to the formulated drug. Ensuring its stability involves evaluating several factors:

• Chemical Stability: The drug molecule itself must remain chemically intact.

• Excipient Compatibility: The active drug must not react negatively with the inactive ingredients (excipients) in the formulation.

• Packaging Options: The packaging must protect the product from environmental degradation factors.

Stability Guidelines

1. The product must have a shelf life of at least $3$ years.

2. Potency must remain $\ge 95\%$ when stored under recommended conditions.

3. The product must look and perform exactly as it did at the time of manufacture.

Chemical Kinetics and Reaction Rates

The rate of degradation is influenced by the number and concentration of reactants. Reaction rates in pharmaceutical science are expressed in terms of time:

• Order of Reaction: Defines the relationship between reactant concentration and the rate of the reaction.

• Half-life ($t_{50}$): The time required for the drug concentration to be reduced by half. This determines dosing frequency, time to effect, and potential risks.

• Shelf-life ($t_{95}$): The time at which there is a $5\%$ loss of drug concentration. For a product with a $3$-year shelf life, the maximum degradation allowed is $5\%$ over those $3$ years.

The Effect of Temperature and the Arrhenius Equation

Thermal effects apply to all four major degradation processes. Generally, a $10\,^{\circ}\text{C}$ increase in temperature can increase the rate of decay by $2$ to $5$ folds.

The relationship between temperature and the rate constant ($k$) is expressed by the simplified Arrhenius Equation:

$k = Ae^{-\frac{E_a}{RT}}$

• $k$: Rate constant (or rate of reaction).

• $A$: Frequency of collisions between molecules.

• $e^{-\frac{E_a}{RT}}$: The fraction of collisions that possess enough energy to trigger a reaction.

• $T$: Temperature, which must be in Kelvin. The conversion is: $\text{Celsius} (^{\circ}\text{C}) = K - 273.15$.

This equation is primarily used during accelerated stability testing to calculate how much a drug will degrade over time.

Detailed Degradation Processes and Mitigation Strategies

Hydrolysis and Solvolysis

• Hydrolysis: The chemical breakdown of molecules by water. It is the most common form of drug degradation.

• Solvolysis: Breakdown by a solvent other than water.

• Hydrolysis occurs naturally during digestion to break down nutrients for easier absorption.

• Catalysts for Breakdown:

  • Presence of hydroxide ($OH^{-}$) or hydronium ($H_{3}O^{+}$) ions.

  • Exposure to heat and light.

  • High drug concentrations.

• Solution: Modify the chemical structure of the drug to make it less susceptible to hydrolysis.

Oxidation

• Oxidation involves the loss of electrons to gain oxygen.

• Environmental Contributors:

  • Light exposure.

  • Trace metals.

  • Presence of oxygen or other oxidizing agents.

• Solution: Include antioxidants in the product formulation.

Photolysis

• Photolysis is the breakdown of molecules via light radiation. Shorter wavelengths of radiation correspond to higher molecular energy.

• UV Light: Has a shorter wavelength and higher energy than visible light.

• Consequences of increased light energy:

  • Molecular decomposition.

  • Conversion of light energy into heat energy.

  • Energy retention or transfer.

  • Light emission at a new wavelength (e.g., fluorescence).

• Solution: Utilize opaque and inert packaging, such as amber glass bottles or aluminum foil blisters.

Trace Metal Catalysis

• Small traces of metals absorbed into the drug (often during manufacturing, shipping, or storage) act as catalysts for degradation.

• Solution: Add chelating agents to the formulation to "cut off" or sequester metal compounds.

Hygroscopicity and Moisture

• Moisture absorption can cause a drug to dissolve itself. This process is highly dependent on relative humidity.

• Hygroscopic Formulations: These are specifically manufactured and stored at low humidity levels.

• Solution: Use impermeable packaging (glass bottles or foil blisters) and add desiccants to the packaging.

Stability Testing Protocols

Regulatory bodies have strict requirements for stability data, which must be established before Preclinical Research can begin. Key data requirements include the expiry date, storage conditions, and comprehensive stability data.

Types of Stability Testing

1. Accelerated Stability Testing: Products are placed under harsher conditions (higher heat/humidity) over a short period (minimum of $6$ months) to obtain results quickly. This is required before Clinical Research/trials.

2. Long-term Stability Testing: Products are placed under milder, recommended storage conditions over a longer period (minimum of $12$ months), resulting in slower data acquisition.

Product Registration and Guidelines

• Step 4 (Product Registration): Requires stability data for $3$ separate production batches stored for the duration of the intended shelf-life (e.g., $3$ years).

• ICH Guidelines: Standardized by the International Council for Harmonisation, specifically the ICH Stability Testing Guidelines Q1A (R2) 2003.

Post-Marketing Safety Monitoring

After the Health Sciences Authority (HSA) or relevant authority authorizes a product for marketing, safety monitoring continues.

• This phase verifies product quality during normal, real-world consumer use.

• While laborious, every step in the stability and monitoring process is essential for ensuring patient safety.